Risperdal Lawsuit $1.2 Billion Verdict Overturned by Arkansas Supreme Court
On March 20, 2014, the Arkansas Supreme Court overturned a trial court award of $1.2 billion to the State of Arkansas against Johnson & Johnson, and its Janssen Pharmaceuticals, Inc. division based on the company’s marketing of the antipsychotic frog Risperdal. This Arkansas lawsuit had been brought by the Arkansas Attorney General and relied on a provision of Arkansas state law governing Medicaid fraud as a basis to challenge the marketing of Risperdal in Arkansas which allegedly included misleading claims about Risperdal’s effectiveness while minimizing risks associated with diabetes.
According to Bloomberg*, Risperdal sales have fallen from a height of $4.5 billion in 2007, to $542 million in 2011, the last year the company reported Risperdal sales.
It should be noted that the Risperdal lawsuit in Arkansas was based on allegations of unfair business practices, not on side effects or personal injuries relating to Risperdal, including Gynecomastia, or abnormal growth of breast tissue in boys and men who have taken Risperdal.
Audet & Partners, LLP continues to offer free case evaluations for Risperdal Gynecomastia claims. For a free, confidential case evaluation with a Risperdal attorney, call Audet & Partners, LLP at (800) 965-1461, or complete and submit our online inquiry form on the right side of this page.
* http://www.bloomberg.com/news/2014-03-20/j-j-gets-1-2-billion-arkansas-risperdal-verdict-tossed.html
